Uncategorized
Replicor Announces Four Appointments to Scientific Advisory Board Doug Kornbrust, Ph.D., D.A.B.T.; Jennifer Lockridge, Ph.D.; Michael Roggendorf, M.D.; and Christian Trepo, M.D., Ph.D.
NEW YORK, April 27 2015 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for Chronic Hepatitis B and D patients, today announced the appointments of four clinical experts to its new Scientific Advisory Board. The company has now completed its first series of proof of concept trials and continues to move toward next…
Read MoreReplicor to Present at the 2015 Lancet Viral Hepatitis Conference
NEW YORK, April 10, 2015 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B (HBV) and hepatitis D (HDV) infection, today announced that it will present updated clinical data at the Lancet Viral Hepatitis Conference in Shanghai, China from April 10-12, 2015. The data are from studies…
Read MoreReplicor to Make Six Presentations at EASL 2015
NEW YORK, April 8, 2015 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B (HBV) and hepatitis D (HDV) patients, today announced that the European Association for the Study of the Liver (EASL) selection committee has accepted six abstracts for presentation at the EASL 2015 annual meeting to be held…
Read MoreReplicor Announces Completion of Enrollment in Phase II Trial
NEW YORK, April 2, 2015 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today announced the completion of enrollment in its latest phase II proof of concept trial (REP 301 protocol). This trial will examine the safety and efficacy of combined REP 2139-Ca and Pegasys®…
Read MoreReplicor a biopharmaceutical company targeting a cure for Chronic Hepatitis B patients will present updated human clinical trial data documenting a 4 to 6 log reduction in s-antigen and a long-term SVR in 80% of patients.
December 1, 2014 – Recently updated clinical trial data from Replicor’s Phase 2 trials will be presented at the Piper Jaffray Healthcare Conference Dec 3rd in New York City. Replicor’s Chief Scientific Officer Dr. Andrew Vaillant Ph.D. will participate in the panel discussion on approaches to treat HBV on Wednesday morning. Replicor’s nucleic acid polymer (NAP)…
Read MoreReplicor to present updated clinical trial data with combination treatment using its HBsAg-release inhibitors in patients with chronic hepatitis B infection at the 10th Annual Meeting of the Oligonucleotide Therapeutics Society.
October 1, 2014 – Updated clinical trial data from Replicor’s three Asian trials using its nucleic acid polymer (NAP) HBsAg-release inhibitors REP 2055 (REP 9AC) and REP 2139-ca (REP 9AC’) will be presented at the 10th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), to be held from Oct 12-16, 2014 in San Diego, CA. Replicor…
Read MoreReplicor announces initiation of its Phase II clinical trial with REP 2139-Ca in combination with Pegasys™ in patients with hepatitis B / hepatitis D co-infection
October 1, 2014 – Replicor announces that the recruitment of patients is underway for its Phase II trial assessing the safety and antiviral efficacy of REP 2139-Ca in combination with Pegasys™ in patients with hepatitis B / hepatitis D (HBV / HDV) co-infection. HDV infection only occurs in patients with an existing HBV infection because HDV…
Read MoreReplicor publishes the initial pre-clinical development of its NAP technology, including REP 2055, for the treatment of chronic HBV infection.
November 2013 – Two papers detailing the initial pre-clinical development of Replicor’s NAP technology for the treatment of chronic HBV infection were published in the November 2013 (Volume 57) edition of the journal Antimicrobial Agents and Chemotherapy. These papers cover the initial in vitro and in vivo studies done with NAP compounds in collaboration with the lab of…
Read MoreReplicor presents clinical efficacy and toxicology results in patients with chronic hepatitis B with short term exposure to immunotherapy after REP 2139-ca induced clearance of serum HBsAg.
14 May 2013, Boston, U.S.A. May 14th, 2013 – Replicor has previously undertaken a proof of concept trial to examine the efficacy of REP 2055 monotherapy in patients with chronic HBV infection. A second proof of concept trial is currently underway in patients with chronic hepatitis B (HBV) undergoing treatment with REP 2139-ca in combination with Zadaxin™…
Read MoreReplicor presents updated clinical efficacy results in patients with chronic hepatitis B with short term exposure to immunotherapy in combination with REP 2139-ca and new clinical data in patients receiving this combination treatment while currently on entecavir (triple combination therapy).
26 April 2013, Amsterdam, Netherlands. April 26th, 2013 – Replicor is currently undertaking a proof of concept trial in patients with chronic hepatitis B (HBV) undergoing treatment with its nucleic acid polymer (NAP) REP 2139-ca in combination with Zadaxin™ or Pegasys™. Updated interim results from this ongoing proof of concept trial as well as new interim…
Read More